Virpax Reports Positive Probudur Results with US Army for Combat Care Study

February 14, 2025

DENVER, Colo., Feb 14, 2025 (247marketnews.com)- Virpax Pharmaceuticals (NASDAQ:VRPX) completed a full study following the initial Probudur pilot study conducted by the U.S. Army Institute of Surgical Research (USAISR), under a Cooperative Research and Development Agreement (CRADA).

The study aimed to evaluate whether Probudur, a local anesthetic, could reduce pain behaviors in a rat model of incisional pain. The study followed the same surgical procedures and assessments as the initial pilot study.

Probudur was compared to free bupivacaine (a commonly used local anesthetic) and EXPAREL (another extended-release formulation of bupivacaine).

Various concentrations of Probudur injected into tissue around the incision site resulted in reduced incision-induced pain behaviors, suggesting its potential effectiveness in pain management.

The positive results from this study are consistent with previous observations by Virpax and encourage the company as they continue to develop Probudur as a potential pain management solution. Probudur is designed to reduce or eliminate the need for opioids after surgery, aiming to provide safe and effective pain control during the perioperative period. The local anesthetic works by binding to sodium channels, preventing pain signals from reaching the brain.

In preclinical studies, Probudur has shown long-duration pain control for at least 96 hours. In the rat incisional model, analgesia lasted up to five days. In vitro studies demonstrated that Probudur has a slow-release mechanism that can release bupivacaine for up to six days, making it a promising option for extended pain relief.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VRPX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.